Roche Holding AG (RO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Roche Holding AG (RO)
Company Performance

Current Price

as of Dec 06, 2024

$311.00

P/E Ratio

20.52

Market Cap

$235.98B

Description

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Metrics

Overview

  • HQBasel, BS
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerRO
  • Price$310.998825+1.38%

Trading Information

  • Market cap$235.98B
  • Float3.64%
  • Average Daily Volume (1m)43,202
  • Average Daily Volume (3m)32,480
  • EPS$14.39

Company

  • Revenue$58.72B
  • Rev growth (1yr)-7.21%
  • Net income$11.50B
  • Gross margin73.06%
  • EBITDA margin33.76%
  • EBITDA$19.82B
  • EV$234.39B
  • EV/Revenue3.99
  • P/E20.52
  • P/S3.73
  • P/B7.53
Documents
Factset
Factset Business Description
Factset Street Account
StreetAccount Consensus Metrics Preview - Roche Holding Q3 Earnings (CHF 251.70, -0.80) (2023-10-18T09:27:41Z)
Roche's to present new key clinical and real-world data for OCREVUS (ocrelizumab) at ECTRIMS-ACTRIMS 2023 (CHF 250.45, 0.00) (2023-10-02T05:03:36Z)
Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types (CHF 238.75, 0.00) (2023-11-14T06:06:12Z)
Roche's Elecsys NfL test granted FDA Breakthrough Device Designation (CHF 238.15, 0.00) (2023-11-09T06:06:05Z)
Roche to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders (CHF 237.50, -0.20) (2023-11-02T13:17:27Z)
Roche notes late-breaking data for BTK inhibitor Fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (CHF 255.30, +2.60) (2023-10-13T13:33:31Z)
Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List (CHF 238.00, 0.00) (2023-11-16T06:03:01Z)
Roche Holding's Phase III ALINA study results: Primary analysis demonstrate a statistically significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint) (CHF 252.50, 0.00) (2023-10-18T05:08:43Z)
New Data for Genentech's Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided (CHF 254.05, 0.00) (2023-10-12T05:03:13Z)
Genentech and NVIDIA enter into strategic AI research collaboration to accelerate drug discovery and development (CHF 236.30, -0.85) (2023-11-21T14:05:24Z)
FDA approves sNDA for Pfizer's Braftovi + Mektovi in certain NSCLC patients, Roche's companion DX (2023-10-12T03:25:10Z)
FDA approves Roche's BLA for Elecsys HTLV-I/II -- letter (CHF 252.50, 0.00) (2023-10-17T20:38:07Z)
Wikipedia
Roche_Holding_AG